Article Figures & Data
Figures
- FIGURE 1.
Histogram of patient numbers vs. serum caffeine levels. Thirty-four percent of patients have zero plasma caffeine, and 66% of patients have detectable caffeine level but all are <0.8 mg/L.
- FIGURE 2.
Changes of diastolic (A) and systolic (B) blood pressures ([BP] mm Hg) associated with dipyridamole infusion vs. serum caffeine levels. Averaged diastolic and systolic blood pressures of all patients are decreased by 3 ± 10 mm Hg and 4 ± 13 mm Hg, respectively, but changes are statistically insignificant.
- FIGURE 3.
Percentage increases of heart rate associated with dipyridamole infusion vs. serum caffeine levels. Heart rate increases are inversely correlated with serum caffeine levels, with r = −0.22 and confidence level of 81% (P = 0.19).
- FIGURE 4.
Averaged heart rate (HR) percentage increases vs. serum caffeine ranges. At point of 5% heart rate increase, serum caffeine level of 2 mg/L is predicted to be lower limit for false-negative dipyridamole 201Tl myocardial perfusion.
Tables
- TABLE 1
Averaged Percentage Heart Rate (HR) Increase and Systolic and Diastolic Blood Pressures (BP) Versus Range of Serum Caffeine Levels
Caffeine level (mg/L) 0 0–0.5 0.5–1.0 HR increase (%) 17.6 ± 9.2 16.3 ± 8.9 11.0 ± 4.5 Systolic BP (mm Hg) −4.6 ± 19 −3.7 ± 8.6 −4.0 ± 8.9 Diastolic BP (mm Hg) −0.2 ± 11 −4.3 ± 10 −2.0 ± 4.5
